Palm Therapeutics

Executive Summary

Palm Therapeutics is a private, early-stage biotechnology company headquartered in San Diego, founded in 2020. It has developed PalmReader, a proprietary high-throughput screening technology that enables the detection of protein palmitoylation. This platform is uniquely capable of identifying novel palmitoylation-modulating molecules thousands of times faster than conventional methods, thereby unlocking a previously undruggable target class. The company's approach holds promise for developing small molecule therapeutics targeting palmitoylation, a post-translational modification implicated in various diseases including cancer and neurodegenerative disorders. While Palm Therapeutics has not yet disclosed specific pipeline programs or raised disclosed funding, its platform technology represents a potential paradigm shift in drug discovery. The absence of publicly available clinical or preclinical data places the company in the discovery phase, but its innovative screening capability could attract strategic partnerships and investment. The company's success hinges on validating its platform through internal or collaborative programs and securing financing to advance toward lead optimization.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round75% success
• Q2 2027Peer-Reviewed Publication or Preclinical Data Release50% success
• Q3 2027Pharma Partnership or Licensing Deal40% success